The significance of transaminase ratio (AST/ALT) in acute myocardial infarction

Dodji Kossi Djakpo, Zhi Quan Wang, Merina Shrestha

Zhongnan Hospital of Wuhan University, Wuhan, China

Submitted: 16 February 2020
Accepted: 26 July 2020

Arch Med Sci Atheroscler Dis 2020; 5: e279–e283
DOI: https://doi.org/10.5114/amsad.2020.103028
Copyright © 2020 Termedia & Banach

Abstract

Introduction: Fernando De Ritis described the significance of the transaminase (AST/ALT) ratio in 1957, and since then it has been commonly used to screen liver diseases. The liver is sensitive to hemodynamic changes because it receives approximately one-quarter of total cardiac output. We aimed to investigate the AST/ALT ratio changes in patients with acute myocardial infarction without any history of liver diseases in the Chinese Han population.

Material and methods: We analyzed a total of 120 patients with acute myocardial infarction admitted to the cardiology department of Zhongnan Hospital of Wuhan University between January 2019 and June 2019. AST/ALT ratio of the first blood test was calculated for all patients.

Results: The mean De Ritis ratio (AST/ALT) was higher in patients with ST-segment elevation myocardial infarction (STEMI) (3.2261 ±2.41379) than in non-ST-segment elevation myocardial infarction (NSTEMI) (2.2089 ±1.63177) patients. The difference was statistically significant (p = 0.002).

Conclusions: AST/ALT ≥ 2.0 has a strong association with total coronary occlusion. We might rely on this test to predict coronary occlusion without age difference.

Key words: De Ritis ratio (AST/ALT), acute myocardial infarction, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction.

Introduction

The ratio of serum aspartate transaminase (AST) and alanine transaminase (ALT) is a commonly used marker of liver diseases. Fernando De Ritis [1] was first to describe the significance of the AST/ALT ratio in 1957. Acute myocardial infarction (AMI) is a global burden and challenging pathology caused by ischemia, resulting in myocardium necrosis and creating a perfusion imbalance as a consequence of the ischemia [2]. The liver is sensitive to hemodynamic changes because it receives approximately one-quarter of total cardiac output [3]. Although abnormal results of transaminases are often observed in patients with myocardial infarction (MI), the significance of the AST/ALT ratio is unknown in this setting. Cardiac biomarkers such as troponins are often elevated during AMI, and ST-segment changes are the parameters most often used to differentiate and evaluate the degree of coronary occlusion. In clinical practice physicians also encounter AMI patients with an initially normal electrocardiogram (ECG), and often perform a coronary angiogram to evaluate the degree of occlusion. Is there any other non-invasive test to evaluate...
the degree of occlusion when there is no evidence of ST-segment changes? We hypothesized that the AST/ALT ratio of the very first blood test at presentation can help evaluate the percentage of occlusion in patients with acute myocardial infarction in the absence of a coronary angiogram. To the best of our knowledge, there are not many available scientific reports that can aid us in verifying our hypothesis. This study aims to investigate the AST/ALT ratio changes in patients with AMI and with no prior history of any kind of liver disease.

Material and methods

This study is a hospital-based prospective observational study conducted in Zhongnan Hospital of Wuhan University, P.R. China. A total of 120 patients who were diagnosed with AMI in the cardiology department of our hospital between January 2019 and June 2019 were randomly enrolled. Patients with a prior history of any liver damage or diseases were excluded from this study. Data were collected from patient medical records. All included patients underwent percutaneous coronary intervention (PCI). Out of all included patients, 76 were ST-segment elevation myocardial infarction (STEMI) patients and 44 were diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI). The diagnosis of NSTEMI and STEMI was made with typical chest pain, 12-lead ECG, and cardiac markers levels [4], according to the European Society of Cardiology (ESC) guidelines [5]. Patients with hepatitis, liver damage, cholestasis, and chronic liver disease were excluded. We also assessed and analyzed the demographic profile of all included patients.

Statistical analysis

AST/ALT ratio of the very first blood test at presentation was calculated for all patients. Patients were divided into two groups as NSTEMI and STEMI according to the MI redefinition. Normality tests were performed for each variable to assess distribution, and statistical analysis of data was performed using IBM SPSS software for Windows version 22. Comparison of means was performed with the independent t-test. The nonparametric data were assessed by the Mann-Whitney U test. A value of \( p < 0.05 \) was considered statistically significant.

Results

Out of 120 enrolled AMI patients in the study, 28 (23.3%) were female and 92 (76.7%) were male. The mean age was 61.43 (61.43 ±13.702). Out of them, 44 were diagnosed as NSTEMI (36.7%) and 76 as STEMI (63.3%) patients. The baseline characteristics of the study population are shown in Table I. In our study, 72 (60.0%) patients had high blood pressure, 48 (40.0%) had a history of smoking, 18 (15.0%) had diabetes mellitus, and 9 (7.5%) patients had recovered from a prior stroke.

The mean AST/ALT ratio of the study group was higher (2.853 ±2.025) compared to the normal range (Table II). The mean De Ritis ratio was higher in patients with STEMI (3.22 ±2.143) than in NSTEMI (2.208 ±1.631) patients. The difference was statistically significant (\( p = 0.002 \)). The Mann-Whitney U test also showed a significant difference between NSTEMI and STEMI (\( p = 0.01 \)). In contrast, there was no significant difference between age groups (Table III). In the old population group (age > 65 years), we also found a higher mean AST/ALT ratio (AST/ALT > 2.0) (Table IV). The ROC curve shows an area under curve of 0.629 (\( p = 0.019; 95\% \) CI: 0.529–0.730) (Figure 1). When the AST/ALT ratio is 0.63, the diagnosis is most effective with a sensitivity of 98.7% and a specificity of 95.5% (Figure 1).

Discussion

The liver is a very important organ, as it plays the role of a blood volume reservoir [6]. It is sensitive to hemodynamic changes because it receives approximately 25% of the total cardiac output [7]. Serum aspartate transaminase (AST) is mainly found in the liver, cardiac muscle, and other tissues while serum alanine transaminase

| Characteristics | N (%) or mean ± SD |
|-----------------|--------------------|
| Age             | 61.43 ±13.702      |
| Female          | 28 (23.3)          |
| Male            | 92 (76.7)          |
| AST/ALT         | 2.853 ±2.025       |
| TnI             | 15622.49 ±18893.57 |
| BNP             | 388.35 ±570.95     |
| CK-MB           | 109.22 ±178.70     |
| WBC             | 9.089 ×10^9 ±3.626 |
| Systolic BP     | 128.52 ±22.551     |
| Diastolic BP    | 77.90 ±13.739      |
| NSTEMI          | 44 (36.7)          |
| STEMI           | 76 (63.3)          |
| Alcohol         | 19 (15.8)          |
| Diabetes mellitus | 18 (15.0)      |
| Dyslipidemia    | 13 (10.8)          |
| Intervention or surgery | 15 (12.5)    |
| Hypertension    | 72 (60.0)          |
| Prior stroke    | 9 (7.5)            |
| Smoking         | 48 (40.0)          |

SD – standard deviation, BP – blood pressure, TnI – troponin I, BNP – brain natriuretic peptide, CK-MB – creatine kinase MB.
The significance of transaminase ratio (AST/ALT) in acute myocardial infarction

ALT is predominantly found in the liver. The ratio of AST to ALT is commonly used to assess liver cell injury [8]. In AMI, AST and ALT are often elevated, especially in STEMI patients [9]. Lofthus et al. recently confirmed in their large study of 1783 patients the elevation of AST in 85.6% and ALT in 48.2% of patients at baseline [10]. In agreement with their study, we also found the ratio of AST to ALT in patients presenting with STEMI more elevated than in NSTEMI patients. In a recent study, Gao et al. also demonstrated the potential association of serum transaminases in STEMI patients [11].

Recent data suggested that the AST/ALT ratio might be a strong predictor for long-term mortality after AMI [11]. A similar study by Steininger et al. showed the long-term prediction mortality after AMI using the ratio of AST to ALT [12]. Steininger et al. found after a median follow-up of 8.6 years that AST (95% confidence interval (CI): 1.09–1.32; \( p < 0.001 \)) and De Ritis ratio (95% CI: 1.18–1.44; \( p < 0.001 \)) were significantly associated with long-term mortality after AMI.

Table II. Population characteristics based on NSTEMI and STEMI

| Characteristics | NSTEMI (n = 44) | STEMI (n = 76) | P-values |
|----------------|----------------|----------------|----------|
| Age            | 62.43 ±12.580  | 60.84 ±14.360  | 0.258    |
| AST/ALT        | 2.208 ±1.631   | 3.22 ±2.143    | 0.002    |
| TnI            | 16587.47 ±19875.71 | 15146.61 ±18512.70 | 0.389 |
| BNP            | 345.90 ±579.52 | 411.99 ±568.94 | 0.524    |
| CK-MB          | 139.53 ±229.82 | 85.85 ±123.84  | 0.010    |
| WBC            | 8.683 × 10^3 ±3.535 | 9.323 × 10^3 ±3.680 | 0.797 |
| SBP            | 136.89 ±20.909 | 123.67 ±22.166 | 0.517    |
| DBP            | 81.68 ±13.166  | 75.71 ±13.670  | 0.913    |

Table III. Population baseline characteristics based on age groups

| Characteristics | < 65 years (n = 70 (58.3%)) | > 65 years (n = 50 (41.7%)) | P-values |
|----------------|-----------------------------|-----------------------------|----------|
| Age            | 51.67 ±8.125                | 75.08 ±6.067                | 0.012    |
| AST/ALT        | 2.752 ±2.007                | 2.994 ±2.061                | 0.702    |
| TnI            | 17269.34 ±19964.64          | 13450.05 ±17351.05          | 0.055    |
| BNP            | 378.94 ±502.70              | 399.87 ±650.08              | 0.146    |
| CK-MB          | 116.71 ±187.73              | 96.81 ±164.78               | 0.558    |
| WBC            | 9.601 × 10^3 ±3.421         | 8.371 × 10^3 ±3.814         | 0.617    |
| SBP            | 126.39 ±19.997              | 131.50 ±25.620              | 0.009    |
| DBP            | 79.69 ±11.851               | 75.40 ±15.802               | 0.022    |

Table IV. Population characteristics based on MI and age groups

| Parameter | Characteristics | NSTEMI (n = 44) | STEMI (n = 76) | P-values |
|-----------|----------------|----------------|----------------|----------|
| n (%)     | 25 (56.8)      | 19 (41.2)      | –              |         |
| AST/ALT   | 2.147 ±1.90    | 2.289 ±1.238   | 0.408          |         |
| WBC       | 8.94 × 10^3 ±3.192 | 8.33 × 10^3 ±4.006 | 0.455       |         |
| n (%)     | 45 (59.2)      | 31 (40.8)      | –              |         |
| AST/ALT   | 3.088 ±2.006   | 3.426 ±2.347   | 0.227          |         |
| WBC       | 9.96 × 10^3 ±3.524 | 8.39 × 10^3 ±3.758 | 0.872       |         |

SD – standard deviation, WBC – white blood cells, SBP – systolic blood pressure, DBP – diastolic blood pressure, TnI – troponin I, BNP – brain natriuretic peptide, CK-MB – creatine kinase MB.
sion. Karwowski et al. proved this hypothesis lately in a large multicenter, observational study of 4581 patients with STEMI and 2717 patients with NSTEMI. Their analysis showed total occlusion [13] in 2949 patients with STEMI (64.4%) and 723 patients with NSTEMI (26.6%). In the last few decades, several similar studies have shown a significant relationship between STEMI and total coronary occlusion [14, 15]. Our study indicated a higher AST to ALT ratio associated with STEMI patients. In this regard, we hypothesized that the elevated De Ritis ratio might also be associated with total occlusion.

In the present study, AST/ALT was calculated from 120 patients – 77 (STEMI) were classified as patients with total occlusion, and 44 (NSTEMI) were grouped as non-total occlusion patients. In total, 46 patients in the STEMI group have an AST/ALT $\geq 2.0$ (mean = 4.54). In the NSTEMI group 19 patients have an AST/ALT $\geq 2.0$ (mean = 3.40). Since STEMI is often associated with total occlusion, we can deduce that AST/ALT $\geq 2.0$ in the STEMI group is also associated with total occlusion. In the case of AMI with an initially normal ECG, the AST to ALT ratio of the very first blood test might be the fastest way to estimate the degree of occlusion. To conclude, based on our investigation, the higher the ratio (AST/ALT $\geq 2.0$) is, the stronger the association with total occlusion is. To better understand the significance of the AST/ALT ratio in AMI, this study also obtained from the ROC curve the optimal cutoff point of 0.63, which corresponds to the greatest sensitivity of 98.7% (Figure 1). However, further investigations with larger populations need to be conducted to confirm our hypothesis.

Age is one of the main risk factors of myocardial infarction. However, our study showed no association with AST/ALT ratio, i.e. that age does not affect the AST/ALT ratio during AMI. Tables III and IV show no significant difference between age groups.

In conclusion, STEMI patients had a significantly increased AST/ALT ratio, and it might be taken into consideration to predict the percentage of occlusion during AMI. AST/ALT $\geq 2$ is a strong predictor of total occlusion during AMI. In summary, in the case of MI with no ST-segment changes, we might rely on the De Ritis ratio to evaluate the degree of coronary occlusion without an age difference.

There are several limitations to the present study. One of the major limitations is that the investigation was a single center-based analysis. No follow-up was done in this study. Unfortunately, our study was not able to investigate full liver function tests of included patients. The current investigation did not include coronary angiogram data.

Conflict of interest
The authors declare no conflict of interest.

References
1. Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev 2013; 34: 117-30.
2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-95.
3. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009; 89: 1269-339.
4. Mueller C, Giannitsis E, Möckel M, et al. Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. Eur Heart J Acute Cardiovasc Care 2017; 6: 218-22.
5. Ibáñez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol 2017; 70: 1082.
6. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol 2010; 16: 6046-57.
7. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971; 51: 23-65.
8. Parmar KS, Singh GK, Gupta GP, Pathak T, Nayak E. Evaluation of De Ritis ratio in liver-associated diseases. Int J Med Sci Public Health 2016; 5: 1783-8.
9. Moon J, Kang WC, Oh PC, et al. Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention. Int J Cardiol 2014; 177: 442-7.
10. Lofthus DM, Stevens SR, Armstrong PW, Granger CB, Mahaffey KW. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coron Artery Dis 2012; 23: 22-30.
11. Gao M, Cheng Y, Zheng Y, Zhang W, Wang L, Qin L. Association of serum transaminases with short- and long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. BMC Cardiovasc Disord 2017; 17: 43.
12. Steininger M, Winter MP, Reiberger T, et al. De-Ritis ratio improves long-term risk prediction after acute myocardial infarction. J Clin Med 2018; 7: 474.

13. Karwowski J, Gierlotka M, Gąsior M, et al. Relationship between infarct artery location, acute total coronary occlusion, and mortality in STEMI and NSTEMI patients. Pol Arch Intern Med 2017; 127: 401-11.

14. Råmunddal T, Hoebers LP, Henriques JPS, et al. Prognostic impact of chronic total occlusions: a report from SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC Cardiovasc Interv 2016; 9: 1535-44.

15. van Dongen IM, Elias J, Meijborg VME et al. Electrocardiographic changes after successful recanalization of a chronic total coronary occlusion. A systematic review and meta-analysis. Cardiovasc Revasculariz Med Mol Interv 2018; 19: 221-8.